The functional anatomy, neurochemistry, and pharmacology of anxiety

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 22, 1999, Pages 12-17

  Ninan, Philip T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOMIPRAMINE; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ALPRAZOLAM; ANTIDEPRESSANT AGENT; BUSPIRONE; CLONAZEPAM; CLONIDINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE MALEATE; LORAZEPAM; UNCLASSIFIED DRUG; YOHIMBINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ANXIOLYTIC AGENT; CYCLOHEXANOL DERIVATIVE;

AMYGDALOID NUCLEUS; ANXIETY NEUROSIS; ARTICLE; AVOIDANCE BEHAVIOR; DEPRESSION; DRUG EFFICACY; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MEMORY; NEUROCHEMISTRY; PRIORITY JOURNAL; COGNITIVE DEFECT; COMORBIDITY; DRUG MECHANISM; FUNCTIONAL ANATOMY; NEUROTRANSMITTER RELEASE; PREFRONTAL CORTEX; REVIEW; ANXIETY DISORDER; DELAYED RELEASE FORMULATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ADRENERGIC UPTAKE INHIBITORS; AMYGDALA; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BUSPIRONE; CLOMIPRAMINE; COMORBIDITY; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; HUMANS; NOREPINEPHRINE; PREFRONTAL CORTEX; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0033369417     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Fawcett J, Kravitz HM. Anxiety syndromes and their relationship to depressive illness. J Clin Psychiatry 1983;44(8, sec 2):8-11
2. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry 1996;168(suppl 30):17-30
3. LeDoux J. The Emotional Brain: The Mysterious Underpinnings of Emotional Life. New York, NY: Simon & Schuster; 1996
4. Davis M. The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 1992;13:35-41
5. Barkley RA. Behav oral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull 1997;121: 65-94
6. Arnsten AF. Biology of being frazzled. Science 1998;280:1711-1712
7. Cahill L, McGaugh JL. Mechanisms of emotional arousal and lasting declarative memory. Trends Neurosci 1998;21:294-299
8. Lamont EW, Kokkinidis L. Infusion of the dopamine D1 receptor antagonist SCH 23390 into the amygdala blocks tear expression in a potentiated startle paradigm. Brain Res 1998;795:128-136
9. Brasfield KH. Practical psychopharmacologic considerations in depression. Nurs Clin North Am 1991;26:651-663
10. Iqbal N, Bajwa W, Asnis GM. Role of norepinephrine in depression. Psychiatr Ann 1989;19:354-359
11. Maas JW. Biogenic amines and depression. Biochemical and pharmacological separation cf two types of depression. Arch Gen Psychiatry 1975; 32:1357-1361
12. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter Clin Chem 1994;40:288-295
13. Richelson E. Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52(6, suppl):4-10
14. Lydiard RB, Brawman-Mintzer O, Ballenger JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol 1996;64:660-668
15. Borne RF. Serotonin: the neurotransmitter for the '90s. Drug Topics 1994; 138:108-117
16. Blier P, De Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226
17. Ninan PT, Cole JO, Yonkers KA. Nonbenzodiazepine anxiolytics. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:287-300
18. Ninan PT, Insel TM, Cohen RM, et al. Benzodiazepine receptor-mediated experimental "anxiety" in primates. Science 1982;218:1332-1334
19. Ashton H. Guidelines for the rational use of benzodiazepines. Drugs 1994; 48:25-40
20. Grimsley SR. Anxiety disorders. In: Young LY, Koda-Kimble MA, eds. Applied Therapeutics: The Clinical Use ot Drugs. 6th ed. Vancouver, British Columbia, Canada: Applied Therapeutics Inc; 1995;sect 73:1-31
21. Birkmayer W, Riederer P. Understanding the Neurotransmitters: Keys to the Workings of the Brain. Blau K, trans. New York, NY: Springer-Verlag Wien; 1989
22. Sevy S, Papadimitriou GN, Surmont DW, et al. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 1989;25:141-152
23. Laird LK, Benefield WH. Mood disorders I: major depressive disorders. In: Young LE, Koda-Kimble MA, eds. Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver, British Columbia, Canada: Applied Therapeutics Inc.; 1995;sect 76:1-28
24. Kalus O, Asnis GM, van Praag HM. Role of serotonin in depression. Psychiatr Ann 1989;19:348-353
25. Paul SM. Anxiety and depression: a common neurobiological substrate? J Clin Psychiatry 1988:49(10, suppl):13-16
26. Heninger GR, Charney DS, Menkes DB. Receptor sensitivity and the mechanism of action of antidepressant treatment. In: Clayton PJ, Barrett JE. eds. Treatment of Depression: Old Controversies and New Approaches. New York, NY: Raven Press; 1983:133-150
27. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and mania. In: Hardman JG, Limbird LE, Molinoff PB, et al, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:431-459
28. Dubovsky SL, Thomas M. Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction. J Psychosom Res 1995:39:429-444
29. Delgado PL, Price LH, Heninger GR, et al. Neurochemistry. In: Paykel ES, ed. Handbook of Affective Disorders. 2nd ed. New York, NY: Guilford Press; 1992:219-253
30. Curtis GC, Abelson JL, Gold PW. Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry 1997;41:76-95
31. Uhde TW, Tancer MH, Gelernter CS, et al. Normal urinary free cortisol and postdexamethasone cortisol in social phobia: comparison to normal volunteers. J Affect Disord 1994;30:155-161
32. Potts NLS, Davidson JRT, Krishnan KRR, et al. Levels of urinary free cortisol in social phobia. J Clin Psychiatry 1991;52(11, suppl):41-42
33. Rosenbaum AH, Schatzberg AF, Jost FA III, et al. Urinary free cortisol levels in anxiety. Psychosomatics 1983;24:835-837
34. Nemeroff CB. Clinical significance of psychoneuroendocrinology in psychiatry: focus on the thyroid and adrenal. J Clin Psychiatry 1989;50 (5, suppl):13-20
35. Lydiard RB, Laraia MT, Ballenger JC, et al. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 1987;144:664-665
36. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-1405
37. Petursson H, Lader MH. Benzodiazepine dependence. Br J Addict 1981; 76:133-145
38. Nierenberg AA. Treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 1994;55(9, suppl A):55-61
39. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
40. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31: 767-771
41. Stein MB, Uhde TW. Biology of anxiety disorders. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. 2nd ed. Washington, DC: American Psychiatric Press; 1998:609-628
42. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998;18:132-135
43. Penava SJ, Otto MW, Pollack MH, et al. Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anxiety 1996-1997;4:240-242
44. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995;10:45-49
45. Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 1999;60(suppl 22):23-28
46. Nelson JC, Mazure CM, Bowers MB Jr, et al. Preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
47. Derivan A, Entsuah AR, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995:31:439-447
48. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998;47:55-62